0001358403-18-000052.txt : 20180615 0001358403-18-000052.hdr.sgml : 20180615 20180615163114 ACCESSION NUMBER: 0001358403-18-000052 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180614 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20180615 DATE AS OF CHANGE: 20180615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201450200 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 18902586 BUSINESS ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 8-K 1 q22018form8-kstockholderme.htm 8-K ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
 
 
FORM 8-K
 
 
 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2018
 
 
 
 
 
Bellicum Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
 
 

Delaware
 
001-36783
 
20-1450200
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
2130 W. Holcombe Blvd., Ste. 800, Houston, TX
 
77030
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (832) 384-1100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).                            
Emerging growth company  ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒





Item 5.07 Submission of Matters to a Vote of Security Holders

On June 14, 2018, Bellicum Pharmaceuticals, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 17, 2018, the record date for the Annual Meeting, 33,656,045 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

A total of 28,260,180 shares of the Company's common stock were present at the meeting in person or by proxy, which represents approximately 83.97% of the shares of common stock outstanding as of the record date for the Annual Meeting.

Proposal 1. Election of Directors

The Company’s stockholders elected the three persons listed below as Class I Directors, each to serve until the Company’s 2021 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The final voting results are as follows:

Name of Director Nominee:
 
Votes For

 
Votes Withheld

 
Broker Non-Votes

Frank B. McGuyer
 
15,230,338

 
1,434,270

 
11,595,572

Jon P. Stonehouse
 
15,348,876

 
1,315,732

 
11,595,572

Stephen R. Davis
 
15,345,641

 
1,318,967

 
11,595,572


Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company's Board of Directors to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. The final voting results are as follows:

 
 
Votes For

 
Votes Against

 
Abstention

 
 
 
 
26,833,365

 
1,369,368

 
57,447

 
 





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
 
 
 
 
 
 
 
Bellicum Pharmaceuticals, Inc.
 
 
 
 
Dated: June 15, 2018
 
 
 
By:
 
/s/ Richard A. Fair
 
 
 
 
 
 
Richard A. Fair
 
 
 
 
 
 
President and Chief Executive Officer
 
 
 
 
 
 
 
Dated: June 15, 2018
 
 
 
By:
 
/s/ Alan A. Musso
 
 
 
 
 
 
Alan A. Musso
 
 
 
 
 
 
Chief Financial Officer and Treasurer
 
 
 
 
 
 
Principal Financial and Accounting Officer